Methylenedioxyallylamphetamine

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Methylenedioxyallylamphetamine
MDAL.png
Names
IUPAC name
N-[1-(1,3-Benzodioxol-5-yl)propan-2-yl]prop-2-en-1-amine
Identifiers
3D model (JSmol)
ChemSpider
Properties
C13H17NO2
Molar mass 219.28 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
☒N verify (what is ☑Y☒N ?)
Infobox references

Methylenedioxyallylamphetamine (MDAL or 3,4-methylenedioxy-N-allylamphetamine) is a lesser-known psychedelic drug. It is also the N-allyl derivative of 3,4-methylenedioxyamphetamine (MDA). MDAL was first synthesized by Alexander Shulgin. In his book PiHKAL, the minimum dosage is listed as 180 mg, and the duration unknown.[1] MDAL produces few to no effects on its own, but may enhance the effects of LSD. Very little data exists about the pharmacological properties, metabolism, and toxicity of MDAL.

Legality[edit]

United Kingdom[edit]

This substance is a Class A drug in the Drugs controlled by the UK Misuse of Drugs Act.[2]

See also[edit]

References[edit]

  1. ^ MDAL entry in PiHKAL
  2. ^ "UK Misuse of Drugs act 2001 Amendment summary". Isomer Design. Retrieved 12 March 2014.